Cypherpunk Technologies Swings to $39M Q2 2026 Profit on Zcash Mark-to-Market Gains

Cypherpunk Technologies reported net income of $39.4 million for Q2 2026, reversing a $16.6 million loss in the year-ago quarter. Results were driven primarily by a $46 million unrealized gain on the company's Zcash (ZEC) holdings. The NASDAQ-listed firm (CYPH) is a former oncology biotech. It previously operated as Leap Therapeutics, rebranded in November 2025, and shifted to a ZEC-focused treasury strategy while reportedly retaining legacy oncology research assets. The strategy pivot was supported by new capital. Winklevoss Capital led a private placement that helped finance the company's accumulation of Zcash tokens. As of early 2026, Cypherpunk is estimated to hold roughly 290,000 to 295,000 ZEC, equivalent to about 1.7% to 1.76% of Zcash's circulating supply. The company acquired the position at an average cost of about $334 to $336 per token. Based on recent prices, the stake is valued at approximately $145 million. Quarterly results have tracked ZEC volatility. In Q1 2026, Cypherpunk posted a net loss of $77.2 million, largely reflecting a $77.6 million unrealized loss after Zcash fell from around $508 to roughly $240. For full-year 2025, the company posted net income of $4.8 million, recovering from a $67.8 million loss in 2024. The 2025 turnaround was supported by about $50.4 million in unrealized gains from its crypto holdings. Zcash is positioned as a privacy-focused cryptocurrency, using zero-knowledge proofs to enable shielded transactions that can validate information without disclosing underlying data. For investors viewing CYPH as a public-market vehicle for ZEC exposure, the core issue is whether the listed structure provides enough benefit—such as liquidity, brokerage accessibility, and potential tax considerations—to offset corporate overhead and governance risk. A key level to watch is ZEC holding above the company's roughly $335 average purchase price. A move below that threshold could quickly translate into unrealized losses that exceed the roughly $77 million hit recorded in Q1.